Resilient Lifescience is an innovative startup focused on developing a wearable medical device designed to automatically detect and reverse opioid overdoses. The company operates in the healthcare technology sector, specifically targeting the opioid crisis, which is a significant public health issue. Their primary clients include healthcare providers, emergency responders, and potentially individuals at high risk of opioid overdose.

The core product of Resilient Lifescience is the Resilient System, a wearable device that uses non-invasive sensing technology to detect Opioid Induced Respiratory Depression (OIRD). This condition occurs when opioid use significantly slows or stops breathing, which can be fatal if not promptly addressed. The device aims to detect these life-threatening events and automatically administer naloxone, a medication that can reverse the effects of an opioid overdose.

Resilient Lifescience operates in the medical device market, which is highly regulated and requires rigorous testing and approval processes. Although their device has not yet been evaluated or cleared for sale by the FDA in the United States, the company is actively involved in research and development, including NSF-sponsored research and human subject studies.

The business model of Resilient Lifescience revolves around the sale of their wearable devices to healthcare institutions and possibly direct-to-consumer sales once regulatory approval is obtained. They generate revenue through the sale of these devices and potentially through subscription services for device monitoring and maintenance.

The leadership team includes experienced professionals like Brad Holden, the Co-founder and CEO, who brings extensive experience from companies like GE Healthcare and Edwards Lifesciences, and Al Moghaddam, the Chief Commercial Officer, who has a background in commercializing medical devices.

In summary, Resilient Lifescience is a forward-thinking company addressing the opioid epidemic with cutting-edge technology. They are currently in the development and testing phase, with a strong focus on bringing their life-saving device to market.

Keywords: wearable medical device, opioid overdose, non-invasive sensing, naloxone, healthcare technology, opioid crisis, FDA approval, research and development, healthcare providers, emergency responders.